BlackRock Discloses 6.0% Passive Stake in Aldeyra Therapeutics
Ticker: ALDX · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1341235
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, biotech
TL;DR
**BlackRock just revealed a 6.0% passive stake in Aldeyra Therapeutics as of year-end 2023.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds 3,747,940 shares of Aldeyra Therapeutics, Inc. common stock. This represents a 6.0% ownership stake in the pharmaceutical company. This filing indicates BlackRock's significant, but passive, investment in Aldeyra, suggesting a long-term belief in the company's prospects without seeking to influence its management.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant stake in Aldeyra Therapeutics, which can signal confidence to other investors.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces risk by showing external confidence.
Analyst Insight
A smart investor would note BlackRock's passive 6.0% stake as a potential vote of confidence, but should still conduct their own due diligence on Aldeyra Therapeutics' fundamentals and future prospects.
Key Numbers
- 3,747,940 — Shares Owned (The total number of Aldeyra Therapeutics common stock shares beneficially owned by BlackRock Inc.)
- 6.0% — Ownership Percentage (The percentage of Aldeyra Therapeutics' common stock owned by BlackRock Inc.)
- December 31, 2023 — Reporting Date (The date as of which BlackRock's ownership stake is being reported.)
Key Players & Entities
- BlackRock Inc. (company) — the filer, reporting its ownership
- Aldeyra Therapeutics, Inc. (company) — the subject company in which shares are owned
- 3,747,940 (dollar_amount) — number of shares of common stock beneficially owned by BlackRock
- 6.0% (dollar_amount) — percentage of Aldeyra Therapeutics' class of securities owned by BlackRock
- December 31, 2023 (person) — the date of the event requiring the filing
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Aldeyra Therapeutics for the foreseeable future. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
Who filed this SC 13G statement?
This SC 13G statement was filed by BlackRock Inc., as indicated in the 'FILED BY' section of the filing.
What company is the subject of this filing?
The subject company of this filing is Aldeyra Therapeutics, Inc., as stated under 'SUBJECT COMPANY' and 'Name of Issuer'.
What percentage of Aldeyra Therapeutics, Inc. common stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 6.0% of Aldeyra Therapeutics, Inc. common stock, as reported in the filing.
How many shares of Aldeyra Therapeutics, Inc. common stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 3,747,940 shares of Aldeyra Therapeutics, Inc. common stock, according to the filing.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as specified in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 by December 31, 2023 regarding Aldeyra Therapeutics, Inc. (ALDX).